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to measure the disruptive effects of influenza on daily ac-
tivities.
METHODS: People with a previous influenza episode were
recruited by newspaper advertisement to discuss the effects
of influenza on their daily activities using a semi-structured
interview technique. Each interview was transcribed, and
a list of statements was generated via content analysis. A
draft instrument was then developed for pilot testing. A
cognitive debrief was included as part of the pilot test to
gain a better understanding of patient’s evaluation of the
adequacy and relevance of the questionnaire. The final
IDDQ was then produced. The IDDQ was administered
in a clinical trial of influenza treatment. The psychomet-
ric properties of the instrument will be reported.
RESULTS: Twelve respondents were interviewed for the
drafting of the IDDQ, while another ten were used in
the pilot testing of the draft eight-item instrument. On
the basis of the pilot testing, one item was re-ordered,
five items were slightly re-worded, and two items were
left unchanged. The final version of the IDDQ has eight
items, each relating to the effects of influenza on disrup-
tion of specific daily activities: self-care; shopping; house-
work; care for others; exercise; social life; hobbies, and
work/school/college. Each item is scored on a five-point,
Likert-type response scale, rated attitudinally from com-
pletely agree to completely disagree.
CONCLUSION: This paper describes the successful de-
velopment of a multi-item questionnaire to measure the
effects of influenza on disruption of daily activities. Psy-
chometric properties of the IDDQ will be presented.
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OBJECTIVE: To compare the cost-effectiveness (CE) of
three competitive surgical procedures for female stress
urinary incontinence (SUI). The three procedures are ret-
ropubic urethral suspension (Burch), urethral sling, and a
new procedure using SURx technology. The study popu-
lation consists of women aged 18 to 85 years who have a
confirmed diagnosis of type I or type II genuine SUI and a
planned surgical treatment procedure. The perspective of
commercial third-party payers is taken for this study.
METHODS: A decision model was developed to com-
pare the costs and effectiveness of the three treatment
strategies for SUI. A hypothetical woman in the study
population is treated with one of the three treatment al-
ternatives and tracked over a period of 12 months. The
CE ratio was defined as cost per cure. Only direct medi-
cal costs were included and estimated by charge data (in
year 2000 dollars). The costs, effectiveness, and outcome
probabilities were collected from InPatientView, the
HCUP Nationwide Inpatient Sample, HCCA Physician
Fee & Coding Guide, the literature, SURx clinical trials,
and expert’s suggestions.
RESULTS: The SURx procedure has the lowest costs
($11,757.22) and the highest effectiveness (0.94). The CE
of the SURx, Burch, and Sling procedures was $12,539.70,
$13,167.85, and $13,736.07 per cure, respectively. Burch
and Sling procedures were dominated by SURx treatment.
The incremental CE of Sling was $52,310.61 per additional
cure relative to Burch. The CE ratio was sensitive to the
hospital and physician costs of each procedure and the
SURx cure rate. The threshold value of the SURx cure rate
was 62%.
CONCLUSIONS: SURx technology for treatment of women
with type I or II genuine SUI is the most cost-effective treat-
ment option as compared to the Burch and Sling proce-
dures. Therefore, SURx may be an appropriate first-line
therapy for SUI.
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OBJECTIVE: An economic model was developed to esti-
mate the comparative cost-effectiveness of treating unstable
bladder (UB) with tolterodine immediate-release (2mg bid),
oxybutynin (5mg bid) and “no treatment” in Italy. The
model uses a one-year timeframe and the payer perspective.
METHODS: The treatment population was based on the
percentage of patients seeking treatment in Italy. The treat-
ment population was divided into successfully treated pa-
tients (STP) and patients failing treatment (PFT). The per-
centage of STP was calculated from clinical efficacy adjusted
by annual persistency. For each group of patients, five cat-
egories of costs were identified: drug costs; incontinence
pads; physician visits; lab tests/diagnostics, and associ-
ated comorbidities. Resource utilization and costs were
obtained from the National Health Service, diagnostic
and hospital codes (diagnostic related groups) and expert
medical panels.
RESULTS: The prevalence of UB sufferers in Italy is esti-
mated to be 12% in 2001 (approximately 7 million peo-
ple), with only 23% of those patients seeking treatment.
STP use fewer pads per day, visit physicians more fre-
quently, have fewer lab tests/diagnostics, and experience
fewer comorbidities than PFT. Efficacy is similar between
tolterodine and oxybutynin. Persistence on therapy is
higher for tolterodine compared to oxybutynin (70% for
tolterodine, 19% for oxybutynin). As a result, effective-
ness is higher for tolterodine than for oxybutynin (42%
for tolterodine, 9.5% for oxybutynin, and 0% for “no
